CIM
ACAD icon

CIM Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

CIM Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
15,273
+1,034
+7% +$22.8K 0.09% 169
2026
Q1 		$317K Hold
14,239
– – 0.08% 189
2025
Q4 		$380K Hold
14,239
– – 0.1% 158
2025
Q3 		$304K Sell
14,239
-15,334
-52% -$363K 0.08% 178
2025
Q2 		$589K Buy
29,573
+14,841
+101% +$276K 0.11% 162
2025
Q1 		$245K Sell
14,732
-350
-2% -$6.36K 0.06% 199
2024
Q4 		$277K Hold
15,082
– – 0.08% 195
2024
Q3 		$232K Hold
15,082
– – 0.07% 211
2024
Q2 		$245K Sell
15,082
-3,588
-19% -$57.9K 0.08% 203
2024
Q1 		$345K Buy
18,670
+8,418
+82% +$209K 0.1% 188
2023
Q4 		$321K Hold
10,252
– – 0.1% 184
2023
Q3 		$214K Hold
10,252
– – 0.08% 238
2023
Q2 		$246K Buy
+10,252
New +$228K 0.08% 222
2018
Q4 		– Sell
-13,593
Closed -$282K – 297
2018
Q3 		$282K Sell
13,593
-1,279
-9% -$20.1K 0.1% 281
2018
Q2 		$227K Buy
+14,872
New +$265K 0.08% 317
2017
Q3 		– Sell
-8,807
Closed -$246K – 316
2017
Q2 		$246K Sell
8,807
-276
-3% -$8.22K 0.09% 317
2017
Q1 		$312K Hold
9,083
– – 0.11% 256
2016
Q4 		$262K Hold
9,083
– – 0.1% 287
2016
Q3 		$289K Buy
9,083
+350
+4% +$11.9K 0.11% 252
2016
Q2 		$283K Buy
+8,733
New +$292K 0.12% 226
2015
Q1 		– Sell
-6,340
Closed -$201K – 258
2014
Q4 		$201K Buy
+6,340
New +$180K 0.09% 237

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CIM Investment Management's ACAD Position: Q2 2026 in Review

CIM Investment Management increased its Acadia Pharmaceuticals (ACAD) stake by 7.3% in Q2 2026, buying an estimated $22.8K and bringing the position to 15,273 shares worth $386K. The position accounts for 0.09% of the portfolio, ranked #169.

CIM Investment Management first reported a position in ACAD in Q4 2014 and has held it in 21 quarters since. The position peaked at $589K in Q2 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • CIM Investment Management held 15,273 shares of Acadia Pharmaceuticals worth $386K as of Q2 2026.
  • CIM Investment Management bought 1,034 Acadia Pharmaceuticals shares in Q2 2026, an estimated $22.8K.
  • Acadia Pharmaceuticals made up 0.09% of CIM Investment Management's portfolio in Q2 2026, its #169 holding.
  • CIM Investment Management first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 21 quarters since.
  • CIM Investment Management's Acadia Pharmaceuticals position peaked at $589K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on CIM Investment Management's 13F filing for Q2 2026, filed 29 Sep 2026.